According to GlobalData’s medical device pipeline database, 38 Transcatheter Mitral Valve Implantation (TMVI) devices are in various stages of development globally. GlobalData’s report Transcatheter Mitral Valve Implantation (TMVI) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 25 are in active development, while the remaining 14 are in an inactive stage of development. There are seven products in the early stages of development, and the remaining 18 are in the late stages of development.
The Transcatheter Heart Valve is an artificial heart valve made up of natural tissue (biological material mainly derived from cow or bovine) surrounded by a flexible mesh frame known as stent (made of steel or cobalt-chromium), all placed in a long narrow tube known as a catheter. The catheter is inserted into a large blood vessel in the groin area (transfemoral) or through a small incision in chest (transapical). Once inside the heart, the valve can then be opened into its natural position by inflation of a balloon and deployed within the patient’s diseased mitral valve. Only Mitral valve replacements are tracked here. One unit refers to one Transcatheter Mitral Valve.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Transcatheter Mitral Valve Implantation (TMVI) pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Transcatheter Mitral Valve Implantation (TMVI) devices. Overall, most of these Transcatheter Mitral Valve Implantation (TMVI) pipeline devices are being developed by private entities.
Key players involved in the active development of Transcatheter Mitral Valve Implantation (TMVI) include Edwards Lifesciences, Neovasc, Valcare Medical, Venus Medtech Hangzhou, 4C Medical Technologies, Abbott Vascular, Annulon, Cardiovalve, Cephea Valve Technologies and Colibri Heart Valve.
For a complete picture of the developmental pipeline for Transcatheter Mitral Valve Implantation (TMVI) devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
